GLP-1s may lower risk for death, heart events among people with hidradenitis suppurativa

GLP-1 receptor agonist therapy was associated with lower all-cause mortality among people with hidradenitis suppurativa — a benefit that lasted up to 2 years, according to a study published in JAMA Dermatology.
These findings were consistent even among patients without diabetes who had HS, according to Beata Jastrząb-Miśkiewicz, MD, PhD, a dermatologist, venereologist and lead investigator of the study.
“It suggests that the association between GLP-1 receptor agonists and improved HS outcomes may not be explained only by better glycemic control,” Jastrząb-Miśkiewicz told Healio. “It raises







